| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1097/00005053-200209000-00002 |
| P698 | PubMed publication ID | 12357091 |
| P2093 | author name string | Daniel J Safer | |
| P433 | issue | 9 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 583-592 | |
| P577 | publication date | 2002-09-01 | |
| P1433 | published in | Journal of Nervous and Mental Disease | Q598644 |
| P1476 | title | Design and reporting modifications in industry-sponsored comparative psychopharmacology trials | |
| P478 | volume | 190 |
| Q47609723 | 'Consumers are patients!' shared decision-making and treatment non-compliance as business opportunity |
| Q33533853 | Appraising evidence for intervention effectiveness in early psychosis: conceptual framework and review of evaluation approaches |
| Q46623804 | Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services |
| Q24288921 | Association of trial registration with the results and conclusions of published trials of new oncology drugs |
| Q35567642 | Can online consumers contribute to drug knowledge? A mixed-methods comparison of consumer-generated and professionally controlled psychotropic medication information on the internet |
| Q82028662 | Chapter 2 Pain as a disease |
| Q46975372 | Clinical perspectives in drug safety and adverse drug reactions |
| Q53113470 | Comparator bias: why comparisons must address genuine uncertainties. |
| Q31042693 | Consent and confidentiality in the light of recent demands for data sharing |
| Q34408516 | DSM-5 changes on the horizon: substance use disorders |
| Q64062502 | Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials |
| Q30350217 | Evidence-based ethics for neurology and psychiatry research. |
| Q40462652 | Explanation and Elaboration Document for the STROBE-Vet Statement: Strengthening the Reporting of Observational Studies in Epidemiology - Veterinary Extension. |
| Q28595548 | Explanation and Elaboration Document for the STROBE-Vet Statement: Strengthening the Reporting of Observational Studies in Epidemiology-Veterinary Extension |
| Q21563421 | Factors associated with findings of published trials of drug-drug comparisons: why some statins appear more efficacious than others |
| Q37799285 | Financial and non-financial conflicts of interests in psychiatry |
| Q52970217 | Implications of pharmaceutical industry funding on clinical research. |
| Q24202591 | Industry sponsorship and research outcome |
| Q64122695 | Industry sponsorship and research outcome: systematic review with meta-analysis |
| Q36088088 | Institutional conflicts of interest: protecting human subjects, scientific integrity, and institutional accountability |
| Q33364538 | Is there evidence for biased reporting of published adverse effects data in pharmaceutical industry-funded studies? |
| Q42317700 | Marketing trials, marketing tricks - how to spot them and how to stop them |
| Q21203737 | Modified versus standard intention-to-treat reporting: are there differences in methodological quality, sponsorship, and findings in randomized trials? A cross-sectional study |
| Q34165083 | Of sophists and spin-doctors: industry-sponsored ghostwriting and the crisis of academic medicine |
| Q24289273 | Outcome Reporting Among Drug Trials Registered in ClinicalTrials.gov |
| Q48557553 | Pain: disease or dis-ease? The John Bonica Lecture: presented at the third World Congress of World Institute of Pain, Barcelona 2004. |
| Q24673248 | Pharmaceutical industry sponsorship and research outcome and quality: systematic review |
| Q50035929 | Primary outcome switching among drug trials with and without principal investigator financial ties to industry: a cross-sectional study |
| Q53091529 | Promoting transparency in pharmaceutical industry-sponsored research. |
| Q38108574 | Publication bias, with a focus on psychiatry: causes and solutions |
| Q64114906 | Randomized clinical trials with run-in periods: frequency, characteristics and reporting |
| Q28474127 | Reporting bias in drug trials submitted to the Food and Drug Administration: review of publication and presentation |
| Q73547549 | Sex, lies, and medical compliance |
| Q28222847 | Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration |
| Q24802626 | Survey on schizophrenia treatment in Mexico: perception and antipsychotic prescription patterns |
| Q26778640 | The Effect of Calcium Sodium Phosphosilicate on Dentin Hypersensitivity: A Systematic Review and Meta-Analysis |
| Q24810516 | The benefits and threats of research partnerships with industry |
| Q34025773 | Those who have the gold make the evidence: how the pharmaceutical industry biases the outcomes of clinical trials of medications |
| Q43159534 | Unbalanced reporting of benefits and harms in abstracts on rofecoxib |
| Q33941732 | Why stop at antidepressants? |
| Q24201550 | Why the Cochrane Risk of Bias Tool Should Include Funding Source as a Standard Item |
| Q28732492 | Why we need easy access to all data from all clinical trials and how to accomplish it |
Search more.